Pharmac Funds New Combination Therapies for Chronic Lymphocytic Leukaemia in NZ

Associate Health Minister David Seymour applauds Pharmac’s decision to fund two new combination therapies—venetoclax with ibrutinib or obinutuzumab—as first-line treatments for chronic lymphocytic leukaemia (CLL), along with expanded access to ibrutinib as a second-line option. These treatments, available from May 2026, aim to improve patient outcomes by enabling longer remission, reducing the need for chemotherapy and hospital visits, and accommodating patient feedback gathered through community consultation. Since the government increased Pharmac’s budget, over 200,000 patients have benefited from funding decisions on 133 medicines, including 46 cancer treatments, reflecting a more collaborative approach with the patient community.